

February 12, 2019

To
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Sub: **Outcome of Board Meeting held on February 12, 2019**

Dear Sir/Madam,

In continuation to our letter dated February 5, 2019, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. February 12, 2019, have

1. Considered & approved the Un-audited financial results of the company for the quarter and nine months ended December 31, 2018.
2. Considered and Noted the Resignation of Mr. Shailesh Mirgal as a Chief Financial Officer of the Company with effect from 4th February, 2019.
3. Approved the appointment of CA Sujit Kumar Dash as a Chief Financial Officer of the Company.
4. Approved the appointment of M/s. Deep Shukla & Associates, Company Secretaries to conduct Secretarial Audit of the Company for financial year ended 31st March, 2019.

In this connection please find enclosed the copy of Un-audited Standalone financial Results of the Company for the quarter and nine months ended December 31, 2018 along with Limited Review Report by the Statutory Auditors of the Company as "Annexure-I" and brief profile of the new Chief Financial Officer appointed as "Annexure- II".




The meeting commenced at 11:00 A.M. and concluded at 1:45 P.M.

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,
For **Kilitch Drugs (India) Limited**



Mukund Mehta
Managing Director
DIN: 00147876



Encl: as above



Annexure - I

A. M. GHELANI & COMPANY **CHARTERED ACCOUNTANTS**

224, Champaklal Industrial Estate
Sion-Koliwada Road, Sion (East),
Mumbai - 400 022.
Tel : 2402 4909 / 8739
Fax : 2407 1138
E-mail : amghelaniandco@gmail.com

AJIT M. GHELANI
B.Com (Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI
B.Com (Hons), F.C.A., C.S

To,
The Board of Directors
Kilitch Drugs (India) Limited


LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2018

1. We have reviewed the accompanying statement of unaudited standalone financial results of KILITCH DRUGS (INDIA) LIMITED (the 'Company') for the quarter and nine months ended 31st December, 2018 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specifies under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company

Chartered Accountants

FRN: 103173W


Chintan Ghelani

Partner

Membership No.: 104391



Place : Mumbai

Dated : 12th February, 2019

Encl: Unaudited financial results for the quarter & nine months ended 31st December, 2018

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2018


Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs.in Lakhs)

Sr. No.	Particulars	STANDALONE					
		Three Months Ended			Nine months Ended		Year Ended
		31-12-18	30-09-18	31-12-17	31-12-18	31-12-17	31/03/2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from operations						
	Net Sales/ Income from operations	1,932.72	2,672.00	1,305.40	7,402.06	3,476.00	5,045.78
	Other Income	32.74	188.69	5.02	458.20	182.39	277.91
	Total Income from Operations	1,965.46	2,860.69	1,310.42	7,860.26	3,658.39	5,323.69
2	Expenses						
	(a) Cost of Materials Consumed	809.23	1,635.05	601.57	4,209.81	1,862.66	2,635.11
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(56.15)	18.42	24.86	(93.05)	(141.79)	(44.20)
	(c) Employee Benefit Expenses	102.85	143.74	108.67	382.96	309.46	421.93
	(d) Finance Cost	-	-	-	-	-	-
	(e) Depreciation and Amortisation Expenses	31.05	29.31	30.33	86.37	88.12	119.23
	(f) Export Product Registration/Commission	213.20	242.02	123.17	519.28	218.68	339.43
	(g) Other Expenses	412.74	179.77	229.68	1,155.86	910.99	1,136.55
	Total Expenses	1,512.92	2,248.31	1,118.28	6,261.23	3,248.12	4,608.05
3	Profit / (Loss) before Exceptional Items (1-2)	452.54	612.38	192.14	1,599.03	410.27	715.64
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	452.54	612.38	192.14	1,599.03	410.27	715.64
6	Tax Expenses:						
	Current Tax	127.61	146.88	10.00	333.61	20.00	33.48
	Deferred Tax	(20.92)	16.85	2.59	54.00	(1.02)	62.57
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	345.85	448.65	179.55	1,211.42	391.29	619.59
8	Other Comprehensive Income (after tax)	(29.24)	(108.05)	139.68	(166.88)	112.97	66.81
9	Total Comprehensive Income (after taxes) (7+8)	316.61	340.60	319.23	1,044.54	504.26	686.40
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,535.52	1,535.52	1,323.18	1,535.52	1,323.18	1,373.18
11	Other Equity						11,746.37
12	Earnings per share						
	(a) Basic (not annualised)	2.14	3.20	1.36	8.38	2.96	4.68
	(b) Diluted (not annualised)	2.14	3.20	1.21	8.38	2.79	4.40

[Handwritten signature]




Notes:

1. The above results as reviewed by the Audit Committee have been taken on record by the Board of Directors at their meeting held on 12th February, 2019.
2. The statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable..
3. The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
4. The IND AS 115 Revenue from Contract with customers, mandatory for reporting periods beginning on or after April 1, 2018, replaces the existing revenue recognition requirements. The application of IND AS 115 has not impacted the company's accounting for recognition of revenue.
5. The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place: Mumbai
Date: 12th February, 2019



For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director



Annexure-II

Brief Profile of Mr. Sujit Kumar Dash:

Full name:	Mr. Sujit Kumar Dash
Date of Birth	15 th May, 1987
Date of Appointment:	February 12, 2019
PAN Number:	ALTPD6823E
Qualifications:	C. A., L.L. B., CMA (Inter), CS (Executive), B. Com.
Experience & Expertise:	Mr. Sujit Kumar Dash is a Member of Institute of Chartered Accountants of India, possessing requisite qualification for the position. He is a Bachelor of Commerce and also possesses Bachelors Degree in Law. He has also completed his Cost Accountancy Final (Group -2) from Institute of Cost and Management Accountants of India along with Company Secretary executive examinations from Institute of Company Secretaries of India. He has vast experience in the field of Finance and Accounts for 6 years from diversified industries. Throwing light in to his abilities, understanding and efficiency, he has the skills required to lead the company with good corporate governance.

